Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
SUPPLEMENTARY TABLE 2. Prespecified outcomes*,† for recombinant zoster vaccine (RZV) in reports submitted to the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
  • Published Date:
    February 28, 2019
  • Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
  • Language:
    English
Filetype[PDF-349.78 KB]


Details:
  • Supporting Files:
    No Additional Files
You May Also Like:
  1. Ensuring the safety of COVID-19 vaccines in the United States
    Corporate Authors:
    National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
    Published Date:
    Oct. 14, 2020
    Description:
    Updated Oct. 14, 2020The U.S. vaccine safety system ensures that all vaccines are as safe as possible. Safety is a top priority while federal partners work to make a coronavirus disease 2019 (COVID-19) vaccine(s) available.
    File Type:
    Filetype[PDF - 186.03 KB]
  2. Adverse events following purified chick embryo cell rabies vaccine in the Vaccine Adverse Event Reporting System (VAERS) in the United States, 2006–2016
    Personal Author:
    Moro, Pedro L.; Lewis, Paige; Cano, Maria;
    Published Date:
    2019 May - Jun
    Source:
    Travel Med Infect Dis. 29:80-81
    File Type:
    Filetype[PDF - 289.06 KB]
  3. SUPPLEMENTARY TABLE 1. Search strategy to identify recombinant zoster vaccine (RZV) reports of selected pre-specified outcomes in the Vaccine Adverse Events Reporting System (VAERS) — United States, October 2017–June 2018
    Published Date:
    February 28, 2019
    Source:
    MMWR. Morbidity and mortality weekly report ; v. 68, no. 4
    Description:
    Supplements: Post-licensure safety surveillance of recombinant zoster vaccine (Shingrix) —Vaccine Adverse Event Reporting System (VAERS), United States, October 2017–June 2018
    File Type:
    Filetype[PDF - 265.31 KB]
  4. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
    Personal Author:
    Hesse, Elisabeth M.; Shimabukuro, Tom T.; Su, John R.; Hibbs, Beth F.; Dooling, Kathleen L.; Goud, Ravi; Lewis, Paige; Ng, Carmen S.; Cano, Maria V.;
    Published Date:
    February 01 2019
    Source:
    MMWR Morb Mortal Wkly Rep. 68(4):91-94
    Description:
    Recombinant zoster vaccine (RZV; Shingrix), an adjuvanted glycoprotein vaccine, was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices for adults aged ≥50 years in October 2017 (1)...
    File Type:
    Filetype[PDF - 180.36 KB]
  5. Cluster anxiety-related adverse events following immunization (AEFI): An assessment of reports detected in social media and those identified using an online search engine
    Personal Author:
    Suragh, Tiffany A.; Lamprianou, Smaragda; MacDonald, Noni E.; Loharikar, Anagha R.; Balakrishnan, Madhava R.; Benes, Oleg; Hyde, Terri B.; McNeil, Michael M.;
    Published Date:
    August 29 2018
    Source:
    Vaccine. 36(40):5949-5954
    Description:
    Background:Adverse events following immunization (AEFI) arising from anxiety have rarely been reported as a cluster(s) in the setting of a mass vaccination program. Reports of clusters of anxiety-related AEFIs are understudied. Social media and the w...
    File Type:
    Filetype[PDF - 554.11 KB]